secwatch.observer — SEC 8-K summary
======================================

Issuer:     Structure Therapeutics Inc. (GPCR)
CIK:        0001888886
Form:       8-K
Filed at:   2024-03-08T23:59:59+00:00
Accession:  0001104659-24-032121
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Structure Therapeutics Q4 net loss $24.5M; cash $467.3M; Phase 2a data due Q2 2024
--------------------------------------------------------------------------------

- Net loss for Q4 2023 was $24.5M ($89.6M full year); compared to $11.9M in Q4 2022.
- Cash and equivalents $467.3M at year-end; expected to fund operations through 2026.
- Topline GSBR-1290 Phase 2a obesity data (12-week) expected latter half of Q2 2024.
- Phase 2b obesity study of GSBR-1290 planned to start Q4 2024.
- R&D expenses $20.0M in Q4 2023 ($70.1M full year), up from $8.4M in Q4 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/0001104659-24-032121-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1888886/000110465924032121/tm248154d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-032121

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer